Pharmaceuticals Company Research Reports

Pharmaceuticals companies are involved into development, production as well as marketing of an extensive variety of medicines. The pharmaceuticals industry is represented by innumerable companies. Small biotechnology and biopharmaceutical manufacturers, mid-sized specialty companies, large multi-nationals enterprises are amid the world pharma companies.

Appearance of new products; introduction of new product costs structures and modes of healthcare delivery; modification of product cost, offerings and design; growing public scrutiny; scientific researches in the fields of nanotechnology, bioengineering, etc. are among trends contributing to changes in the pharmaceutical industry.

Johnson & Johnson, Pfizer, Inc., Roche Holding AG, Novartis International AG, Abbott Laboratories, etc. are amid behemoths of the pharmaceutical industry.

Within this MarketPublishers’ catalogue there are innumerable reports featuring pharmaceutical companies’ overviews. The research reports provide a state-of-the-art picture of the pharma market including the analyses of the pharmaceuticals companies. Evaluation of companies’ strategies and data on products offerings are available in the research studies.

Found 5599 publications
3-V Biosciences, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and its locations and subsidiaries The report reviews current pipeline of 3-V Biosciences, Inc.’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the 3-V Biosciences, Inc.’s pipeline products ...

Jun, 2014 23 pages
SignPath Pharma Inc - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the SignPath Pharma Inc’s pipeline products Reasons to ... of focus Identify new drug targets and therapeutic classes in the SignPath Pharma Inc’s R&D portfolio and develop key strategic initiatives to reinforce ...

Jun, 2014 22 pages
Pharmicell Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Pharmicell Co., Ltd.’s human therapeutic ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Pharmicell Co., Ltd.’s pipeline products ...

Jul, 2014 32 pages
NuCana BioMed Limited - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the NuCana BioMed Limited’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the NuCana BioMed Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Jul, 2014 34 pages
Microbio Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Microbio Co., Ltd.’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Microbio Co., Ltd.’s pipeline products ...

Jul, 2014 28 pages
International Stem Cell Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... . Scope The report provides brief overview of International Stem Cell Corporation including business description, key information and facts, and its ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the International Stem Cell Corporation’s pipeline products ...

Jun, 2014 20 pages
GNI Group Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the GNI Group Ltd.’s pipeline products Reasons to ...

Jun, 2014 26 pages
Ferring International Center S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Ferring International Center S.A.’s pipeline products Reasons ...

Jul, 2014 46 pages
Phylogica Limited - Product Pipeline Review - 2014 US$ 1,500.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Phylogica Limited’s pipeline products ... areas of focus Identify new drug targets and therapeutic classes in the Phylogica Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Jul, 2014 22 pages
Genexine, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Genexine, Inc.’s pipeline products ... drug targets and therapeutic classes in the Genexine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Jul, 2014 32 pages
Dong Wha Pharma Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... disease. Scope The report provides brief overview of Dong Wha Pharma Co., Ltd. including business description, key information and facts, and its ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Dong Wha Pharma Co., Ltd.’s pipeline products ...

Jul, 2014 32 pages
Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014 US$ 2,000.00

... Dermatoses - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014’, provides an overview of the Corticosteroid-Responsive Dermatoses’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development ...

Jun, 2014 33 pages
SIFI S.p.A - Product Pipeline Review - 2014 US$ 1,500.00

... Summary Global Markets Direct’s, ‘SIFI S.p.A - Product Pipeline Review - 2014’, provides an overview of the SIFI S.p.A’s pharmaceutical research and development focus. This ... type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued ...

Jun, 2014 27 pages
Lipicard Technologies Limited - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Lipicard Technologies Limited’s pipeline products Reasons to ...

Jun, 2014 57 pages
ARA Healthcare Pvt. Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... disease. Scope The report provides brief overview of ARA Healthcare Pvt. Ltd. including business description, key information and facts, and its ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the ARA Healthcare Pvt. Ltd.’s pipeline products ...

Jun, 2014 33 pages
OctoPlus N.V. - Strategic SWOT Analysis Review US$ 300.00

... ’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key ... – Progression of key events associated with the company. Major products and services – A list of major products, services and brands of the company ...

May, 2014 21 pages
21st Century Oncology, Inc. - Strategic SWOT Analysis Review US$ 125.00

... on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to ... facilities – A list of key manufacturing facilities of the company. Highlights 21st Century Oncology, Inc. (21st Century Oncology), formerly Radiation Therapy services, ...

Jun, 2014 26 pages
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014 US$ 2,000.00

... Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic’s Syndrome), complete with ...

May, 2014 64 pages
Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014 US$ 2,000.00

... Direct’s, ‘Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014’, provides an overview of the Exocrine Pancreatic Insufficiency’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative ...

May, 2014 42 pages
UDG Healthcare plc (UDG) - Financial and Strategic SWOT Analysis Review US$ 125.00

... financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights UDG Healthcare plc ... the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated ...

May, 2014 37 pages
MModal Services, Ltd., Inc. - Strategic SWOT Analysis Review US$ 125.00

... key locations and subsidiaries of the company, including contact details. Key manufacturing facilities – A list of key manufacturing facilities of the company. Highlights MModal Services, Ltd., Inc. (MModal) is a provider of clinical transcription services and clinical documentation workflow solutions. ...

Apr, 2014 26 pages
K-V Pharmaceutical Company - Financial and Strategic SWOT Analysis Review US$ 125.00

... of the company’s business strategy. SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. Company history – Progression of key ... with 5 years history. Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/ ...

May, 2014 33 pages
Healthcare Locums Limited - Strategic SWOT Analysis Review US$ 125.00

Healthcare Locums Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and ... analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will ...

Apr, 2014 23 pages
Cortex Pharmaceuticals, Inc. (COR) - Strategic SWOT Analysis Review US$ 125.00

Cortex Pharmaceuticals, Inc. (COR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and ... on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to ...

May, 2014 24 pages
Cellectar Biosciences, Inc. (CLRB) - Financial and Strategic SWOT Analysis Review US$ 125.00

... ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Cellectar Biosciences, Inc. ... the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated ...

Jun, 2014 44 pages
Actavis plc (ACT) - Financial and Strategic SWOT Analysis Review US$ 125.00

... the company’s business strategy. SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. Company history – Progression of key events ... the company with 5 years history. Interim ratios for the last five interim periods – The latest financial ratios derived from the ...

Apr, 2014 53 pages
Laboratorios Farmaceuticos Rovi, S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Laboratorios Farmaceuticos Rovi, S.A.’s pipeline products Reasons to ...

Apr, 2014 28 pages
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014 US$ 2,000.00

... RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ... and discontinued pipeline projects A review of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and ...

Apr, 2014 42 pages
Acura Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Acura Pharmaceuticals, Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Acura Pharmaceuticals, Inc.’s pipeline products Reasons ...

Apr, 2014 32 pages
Receptos, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Receptos, Inc.’s pipeline products ... drug targets and therapeutic classes in the Receptos, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Apr, 2014 28 pages
Purdue Pharma L.P. - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Purdue Pharma L.P.’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Purdue Pharma L.P.’s pipeline products ...

Apr, 2014 35 pages
MI.TO. Technology S.r.L. - Product Pipeline Review - 2014 US$ 1,500.00

... (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the MI.TO. Technology S.r.L.’s pipeline products Reasons ...

Apr, 2014 27 pages
Mertiva AB - Product Pipeline Review - 2014 US$ 1,500.00

... Summary Global Markets Direct’s, ‘Mertiva AB - Product Pipeline Review - 2014’, provides an overview of the Mertiva AB’s pharmaceutical research and development focus. This ... type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued ...

Apr, 2014 21 pages
Genor BioPharma Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Genor BioPharma Co., Ltd.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Genor BioPharma Co., Ltd.’s pipeline products Reasons to ...

Apr, 2014 38 pages
Genelux Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Genelux Corporation’s human therapeutic ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Genelux Corporation’s pipeline products ...

Apr, 2014 24 pages
Fujifilm Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Fujifilm Corporation’s human therapeutic ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Fujifilm Corporation’s pipeline products ...

Apr, 2014 25 pages
DBV Technologies - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the DBV Technologies’s pipeline products ... areas of focus Identify new drug targets and therapeutic classes in the DBV Technologies’s R&D portfolio and develop key strategic initiatives to reinforce ...

Apr, 2014 32 pages
Curaxys, S.L. - Product Pipeline Review - 2014 US$ 1,500.00

Summary Global Markets Direct’s, ‘Curaxys, S.L. - Product Pipeline Review - 2014’, provides an overview of the Curaxys, S.L.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Curaxys, S.L.’s, complete with ...

Apr, 2014 22 pages
Chronic Cough - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Chronic Cough - Pipeline Review, H1 2014’, provides an overview of the Chronic Cough’s therapeutic pipeline. This report provides ... type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

Apr, 2014 49 pages
Catalyst Pharmaceutical Partners, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Catalyst Pharmaceutical Partners, Inc.’s pipeline products ...

Apr, 2014 40 pages
Cardiolynx AG - Product Pipeline Review - 2014 US$ 1,500.00

Summary Global Markets Direct’s, ‘Cardiolynx AG - Product Pipeline Review - 2014’, provides an overview of the Cardiolynx AG’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cardiolynx AG’s, complete with ...

Apr, 2014 36 pages
BRAINco Biopharma, S.L. - Product Pipeline Review - 2014 US$ 1,500.00

... its locations and subsidiaries The report reviews current pipeline of BRAINco Biopharma, S.L.’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the BRAINco Biopharma, S.L.’s pipeline products ...

Apr, 2014 20 pages
BioInvent International AB - Product Pipeline Review - 2014 US$ 1,500.00

... report reviews current pipeline of BioInvent International AB’s human therapeutic division and enlists all their major and minor projects The report ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the BioInvent International AB’s pipeline products ...

Apr, 2014 34 pages
Activaero GmbH - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Activaero GmbH’s pipeline products ... drug targets and therapeutic classes in the Activaero GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Apr, 2014 30 pages
Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Wroclawskie Centrum Badan EIT+ Sp. z o.o.’s pipeline products ...

Mar, 2014 16 pages
Visceral Pain - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H1 2014’, provides an overview of the Visceral Pain’s therapeutic pipeline. This report provides ... type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

Mar, 2014 41 pages
Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Serendex Pharmaceuticals A/S’s pipeline products ...

Mar, 2014 23 pages
Orphazyme ApS - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Orphazyme ApS’s pipeline products ... drug targets and therapeutic classes in the Orphazyme ApS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 25 pages
Natco Pharma Limited - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Natco Pharma Limited’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the Natco Pharma Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Mar, 2014 27 pages
ImmunGene, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the ImmunGene, Inc.’s pipeline products ... drug targets and therapeutic classes in the ImmunGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 19 pages
1 2 3 4 5 >
Skip to top